Bachert C, Han JK, Desrosiers M, et al. - Through LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52, two multinational, multicentre, randomized, double-blind, placebo-controlled, parallel-group studies of 276 individuals aged 18 years or older with bilateral chronic rhinosinusitis with nasal polyps (CRSwNP) and symptoms irrespective of intranasal corticosteroid use, who received systemic corticosteroids in the past 2 years or who had sinonasal surgery, researchers evaluated efficiency and safety of dupilumab in patients with CRSwNP notwithstanding the former treatment with systemic corticosteroids, surgery, or both. Dupilumab diminished polyp size, sinus opacification, and severity of symptoms in adult patients with severe CRSwNP and was concluded as well tolerated. This supports the advantages of adding dupilumab to a daily standard of care for patients with critical CRSwNP who contrarily have some therapeutic options.